Lipocine
LPCN
32 hedge funds and large institutions have $12.8M invested in Lipocine in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 13 increasing their positions, 4 reducing their positions, and 14 closing their positions.
559% more call options, than puts
Call options by funds: $1.99M | Put options by funds: $301K
225% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 4
3% more capital invested
Capital invested by funds: $12.4M → $12.8M (+$396K)
0.06% more ownership
Funds ownership: 0.55% → 0.61% (+0.06%)
24% less funds holding
Funds holding: 42 → 32 (-10)
71% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.04M |
| 2 |
State Street
Boston,
Massachusetts
|
+$404K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$319K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$217K |
| 5 |
Mercer Global Advisors
Denver,
Colorado
|
+$113K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$289K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$199K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$130K |
| 4 |
Squarepoint
New York
|
-$127K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$83K |
LPCN Hedge Fund Activity: Q2 2021 in Review
32 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q2 2021, worth a combined $12.8M — up 3.2% from $12.4M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of LPCN and 4 opened new positions — a net loss of 10 holders — while 4 trimmed existing stakes and 13 added.
The largest buyer was Morgan Stanley, adding an estimated $1.04M. The largest seller was Virtu Financial, exiting entirely with an estimated $289K sold.
- 32 institutional investors held Lipocine (LPCN) as of Q2 2021, down from 42 in Q1 2021.
- Funds reported $12.8M of Lipocine stock for Q2 2021, up 3.2% quarter-over-quarter.
- 4 funds opened new Lipocine positions in Q2 2021 and 14 closed out, a net change of -10 holders.
- The largest Lipocine buyer in Q2 2021 was Morgan Stanley, an estimated $1.04M added.
- The largest Lipocine seller in Q2 2021 was Virtu Financial, an estimated $289K sold.
Based on aggregated 13F filings for Q2 2021.